Cartesian Therapeutics Income Statement (2015-2026) | RNAC

1Y3Y5Y7Y10YAll
Download Data
Income Statement Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
3.85M4.12M4.15M5.09M5.10M5.10M5.11M5.11M5.16M5.40M5.52M17.82M23.90M17.28M25.94M26.00M26.00M26.01M28.54M30.04M
Revenue & cost
Revenue (Quarter)
24.43M29.94M34.00M39.27M20.71M16.80M5.94M5.25M6.55M8.27M5.84M33.27M-0.84M1.10M0.95M0.08M
Operating items
Research & Development (Quarter)
20.95M20.32M17.69M19.18M16.54M18.97M18.62M17.78M13.00M21.85M9.74M12.66M11.40M11.31M14.67M14.87M13.80M14.69M19.46M20.43M
Selling, General & Administrative (Quarter)
5.45M5.54M5.54M6.23M5.77M6.32M5.70M6.11M6.61M22.04M9.45M7.03M6.56M7.09M8.31M7.24M7.72M8.20M7.11M8.72M
Other Operating Expenses (Quarter)
0.71M7.58M56.70M
Operating Expenses (Quarter)
26.40M25.86M23.23M25.41M22.31M25.29M24.32M23.89M19.62M44.60M19.19M19.69M17.96M25.97M22.99M22.11M21.52M79.59M26.58M29.16M
Operating Income (Quarter)
-1.97M4.08M10.77M13.86M-1.60M-8.50M-18.38M-18.64M-13.06M-36.33M-13.35M13.76M-17.57M-26.73M-21.89M-21.81M-21.07M-78.64M-26.50M-29.16M
EBIT (Quarter)
-1.97M4.08M10.77M13.86M-1.60M-8.50M-18.38M-18.64M-13.06M-36.33M-13.35M13.76M-17.57M-26.73M-21.89M-21.81M-21.07M-78.64M-26.50M-29.16M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.01M0.01M0.21M0.71M0.02M0.01M1.39M4.95M1.16M1.20M2.57M2.45M2.02M1.75M1.55M1.27M1.03M1.10M
Other Non Operating Income (Quarter)
-0.50M0.52M0.15M0.00M-0.18M0.26M0.02M-0.00M-149.64M-6.89M0.29M0.25M7.50M-0.00M0.13M
Non Operating Income (Quarter)
-43.48M0.08M-6.61M16.77M4.18M37.70M-14.84M-23.13M-12.68M44.92M
Net income details
EBT (Quarter)
-2.07M12.38M10.08M13.35M-8.21M5.61M-19.18M-18.00M-9.00M-196.66M-24.88M-18.13M-30.21M-25.29M-20.19M-37.09M-24.61M-78.51M-26.64M-41.69M
Tax Provisions (Quarter)
15.83M0.14M-0.32M-0.29M
Profit After Tax (Quarter)
-17.90M12.24M28.78M8.60M-7.94M5.90M-21.66M-11.39M-9.02M-177.66M-56.82M13.84M-24.20M-10.25M-17.71M15.89M-35.90M-92.61M-39.18M15.77M
Income from Continuing Operations (Quarter)
-17.89M12.24M10.08M13.35M-7.89M5.89M-19.18M-18.00M-9.00M-196.66M-24.88M-18.13M-30.21M-25.29M-20.19M-37.09M-24.61M-78.51M-26.64M-41.69M
Consolidated Net Income (Quarter)
-17.89M12.24M10.08M13.35M-7.89M5.89M-19.18M-18.00M-9.00M-196.66M-24.88M-18.13M-30.21M-25.29M-20.19M-37.09M-24.61M-78.51M-26.64M-41.69M
Income towards Parent Company (Quarter)
-17.89M12.24M10.08M13.35M-7.89M5.89M-19.18M-18.00M-9.00M-196.66M-24.88M-18.13M-30.21M-25.29M-20.19M-37.09M-24.61M-78.51M-26.64M-41.69M
Preferred Dividend Payments (Quarter)
4.21M2.63M2.05M
Net Income towards Common Stockholders (Quarter)
-17.89M12.24M10.08M13.35M-7.89M5.89M-19.18M-11.39M-9.00M-196.66M-24.88M9.63M-30.21M-25.29M-20.19M13.26M-24.61M-78.51M-26.64M13.72M
Additional items
EPS (Basic) (Quarter)
-4.663.212.432.70-1.551.22-3.75-2.23-1.74-38.04-4.590.58-1.41-1.46-0.780.51-0.95-3.02-0.990.47
EPS (Diluted) (Quarter)
-4.663.212.372.70-1.551.21-3.75-2.23-1.74-38.04-4.590.54-1.41-1.46-0.780.50-0.95-3.02-0.990.46
Shares Outstanding (Quarter)
3.84M3.81M4.14M4.95M5.09M4.82M5.11M5.11M5.16M5.17M5.41M16.72M21.47M17.28M25.90M25.98M26.00M25.97M26.86M29.47M
Shares Outstanding (Diluted) (Quarter)
3.84M3.81M4.25M4.95M5.09M4.86M5.11M5.11M5.16M5.17M5.41M17.79M21.47M17.36M25.90M26.45M26.00M25.97M26.86M29.86M
EBITDA (Quarter)
-1.97M4.08M10.77M13.86M-1.60M-8.50M-18.38M-18.64M-13.06M-36.33M-13.35M13.76M-17.57M-26.73M-21.89M-21.81M-21.07M-78.64M-26.50M-29.16M
Interest Expenses (Quarter)
0.71M-0.13M0.71M0.71M0.80M1.64M0.81M0.75M1.27M130.46M12.69M33.08M15.21M1.01M0.32M17.02M5.09M1.14M1.17M13.63M
Tax Rate (Quarter)
-766.121.113.91-5.14